Karolinska Fund

9 November 2007 – Dr. Fritz Frickel Named Chairman of the Board of Sidec

Dr. Frickel has a solid background in the pharmaceutical industry as Senior Vice President Pharmaceuticals Research for Abbott Laboratories, responsible for target identification/validation, assay development and medicinal chemistry in the area of CNS. He led the Development Activities in the US for BASF, has extensive experience in clinical development and regulatory issues as well as experience in strategic marketing and Phase IV studies with Knoll AG. Dr. Frickel was recently the CEO for Alantos; Alantos Pharmaceuticals is a Cambridge (US) and Heidelberg located Biopharmaceutical Company dedicated to the discovery and development of "best in class" small molecule drugs for inflammation and metabolic diseases. Dr. Frickel has a PhD in chemistry.



NEWS, Karolinska Investment Fund


December 21, 2007: Sidec Technologies Sidec Receives Second Tranch of SEK 34.3 million December 18, 2007: WILEX WILEX updates the status of the RENCAREX¨ Phase III-ARISER Study following the positive interim analysis for futility December 13, 2007: WILEX WILEX announces positive result of the interim analysis for futility of its Phase III ARISER trial with RENCAREX¨ December 12, 2007: NsGene NsGene A/S begins Phase Ib clinical trial with NsG0202 for the treatment of AlzheimerÕs disease November 9, 2007: Sidec Technologies Dr. Fritz Frickel Named Chairman of the Board of Sidec October 12, 2007: WILEX WILEX second product enters Phase III trial: IND approval from FDA for registration trial with CA9-SCAN October 11, 2007: WILEX WILEX Q3 report 2007: progress with development projects Ð 2007 financial outlook confirmed October 1, 2007: WILEX Supervisory Board appoints Thomas Borcholte as Chief Business Officer and member of the Executive Management Board of WILEX AG September 24, 2007: WILEX Phase Ib trial with WX-671 in patients with head & neck cancer successfully completed September 12, 2007: Cellectricon Cellectricon Announces WorldÕs First System for High Throughput RNAi Screening September 5, 2007: Genizon Genizon BioSciences Publishes Novel Genes for Crohn's Disease August 27, 2007: CanAg NSE EIA CanAg NSE EIA - Product improvment July 12, 2007: WILEX WILEX HY1 2007: projects in line with expectations – improved financial outlook July 3, 2007: WILEX First international symposium on functional and clinical aspects of the tumour antigen CA-IX to be held on 14 November 2007 in Brussels June 29, 2007: WILEX WILEX to follow FDA advice and apply for a special protocol assessment (SPA) for CA9-SCAN June 26, 2007: WILEX Patient recruitment started in clinical Phase II trial with WX-671 in pancreatic cancer June 13, 2007: WILEX Annual General Meeting appoints new Supervisory Board members June 6, 2007: Cellectricon Cellectricon introduces the Dynaflow!" Temperature Control System June 6, 2007: Cellectricon With the Cellaxess!" CX1 and CX3 systems neuronal tissue slices and primary neuronal cultures can finally be efficiently transfected with excellent viability May 8, 2007: Sidec Technologies Sidec Technologies secures SEK 68,5 Million in Venture Funding April 13 2007: WILEX The Munich-based biopharmaceutical company WILEX AG (ISIN DE0006614720/Frankfurt Stock Exchange/Prime Standard) today published its results and report for the first quarter of 2007 (1 December 2006 - 28 February 2007). The results are in line with the Company's expectations. April 3, 2007: WILEX The Munich-based biopharmaceutical company WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) announced today that, in its pivotal Phase III study of RENCAREX" – (the data of which are required for European and US filing for approval) over 420 of 856 patients planned have been enrolled. The international, multicentre, randomised trial, called ARISER (Adjuvant Rencarex Immunotherapy trial to Study Efficacy in non-metastasized Renal cell carcinoma), examines the efficacy of the antibody RENCAREX" – in comparison to placebo for the treatment of clear cell renal cell cancer patients after complete or partial surgical removal of the affected kidney in patients with no detectable metastases. This cancer belongs to one of the particularly aggressive indications. RENCAREX" – aims to inhibit these malignant kidney tumours from further growth and recurrence and to help to kill cancer cells and thereby prolong the disease-free survival of patients. March 14, 2007: Sidec Technologies Sidec "s customer issues press release on new findings. New insights to novel mechanism of action of HuMax-EGFr revealed by Protein Tomography!". March 1, 2007: NsGene Capital Infusion of DKK 40 million to NsGene from its Shareholders February 27, 2007: WILEX The Munich-based biopharmaceutical company WILEX AG (ISIN DE0006614720/Frankfurt Stock exchange/Prime Standard) today published its results and annual report for financial year 2006 (1 December 2005 - 30 November 2006). Operating income, operating expenses and earnings are all in line with the Company's expectations. February 13, 2007: Gyros Gyros introduces new product for high concentration protein quantification February 13, 2007: Gyros Gyros completes five new sales of its Gyrolab"–protein quantification platform February 6, 2007: Eipcure EPICURE: An EU funded FP6 project looking at Functional A Basis for New Therapeutic Strategies February 5, 2007: Genizon BioSciences GENIZON SECURES $10 MILLION IN ADDITIONAL FINANCING Pfizer Inc. joins as new investor January 28, 2007: AngioGenetics New mechanism for blood vessel growth discovered – may be important for cancer treatment. January 16, 2007: Genizon BioSciences Genizon Biosciences Announces a License and Collaboration Agreement with Pfizer in Three Major Diseases

Karolinska Fund - News